Purpose: To develop a novel surgical approach to provide consistent delivery of cell suspension into the subretinal space without cell leakage into the vitreous.
C ell-based therapies are of great interest for the treatment of macular degeneration and other retinal diseases that result in loss of the retinal pigment epithelium or retinal cell layers. There are currently several human clinical trials underway to evaluate the safety and efficacy of cell-based therapy. 1, 2 Many of these trials have as a common element the delivery of suspensions of cells to the subretinal space through a cannula. The surgical approach to delivering these cells could be a substantial factor in the success of the procedure and the type of complications that might occur as a result of surgery. For instance, there is likely to be an optimal concentration or absolute number of cells to deliver to the subretinal space. But passage of cells through cannulas may lead to cell death, so that the actual number of cells delivered to the subretinal space is less than expected. Additionally, if cells are injected transretinally through a vitreous approach, there is likely to be some loss of cells through the injection site. 3 This loss of cells into the vitreous (leakage) reduces the number of cells in the subretinal space, and could potentially lead to membrane formation on the surface of the retina. Such membrane formation might increase the possibility of retinal detachment and proliferative vitreoretinopathy.
In this study, we have evaluated the effect of different cannula sizes on the recovery and viability of cells. In addition, we have documented the leakage of cells during transretinal injection of the cells from a vitreous approach. Based on these evaluations, we have developed a novel method for transplanting cells in the subretinal space that maximizes cell viability, minimizes loss of cells, and minimizes escape of cells into the vitreous cavity.
Methods

Determining Appropriate Cannula Size
Green fluorescent protein (GFP)-labeled human induced-pluripotent stem cell (iPSC)-derived retinal pigment epithelium cells (courtesy of Kapil Bharti) were trypsinized and resuspended at a concentration of 10,000 cells per microliter divided into 3 centrifuge tubes containing 100 mL and 1 tube containing 30 mL. For each 100-mL aliquot, the cell suspension was drawn up into microtubing connected to a 250-mL Hamilton syringe through a blunt-tipped 18-g needle. Once the cell suspension was drawn fully into the tubing, the 18-g needle was replaced with either a 30 g, 38 g, or 41 g subretinal injection cannula. The suspension was then pushed to the tip of the cannula. Five 10-mL injections into new centrifuge tubes were performed for each cannula gauge. These 10-mL injections were diluted in BSS+ and Trypan blue. Cells were counted for each injection providing five counts per cannula. Control counts were made from the single tube containing 30 mL. For these, 10-mL aliquots were pipetted into 3 new centrifuge tubes and diluted in BSS+ and Trypan blue.
Surgical Approaches
Evaluation of surgical approaches to cell delivery was carried out in rhesus macaques. A pars plana without vitrectomy approach was used to create a subretinal bleb with balanced salt solution using a 41-gauge cannula. Based on findings from the in vitro cell recovery and viability experiments, cell injections were performed with 30-gauge cannulas. The cells (10,000 cells per microliter; 50 mL total Fig. 1 . Illustrations of the surgical approach for transscleral delivery of cell suspension resulting in high success rates that places cells within the subretinal space without leakage into the vitreous. A. Subretinal bleb (B; blue; 300 mL) is created using a 41-gauge cannula. The location of the bleb is marked externally and the eye is rotated to ease access to location for injection (C), cells are injected into the subretinal bleb using a 30-gauge cannula (D; green). The eye is then returned to resting position (E) and examined using an indirect ophthalmoscope to ensure proper location of the delivered cells. F. Illustration of rotation of the right eye and marking the location at which the injection cannula will be inserted, seen in (G).
volume) were injected into the subretinal space with 2 different approaches. In 8 eyes of 4 animals, cells were injected transretinally into the subretinal space (within the previously created saline bleb) using a 30-gauge cannula, while maintaining intraocular pressure with a combined light pipe infusion cannula. In 16 eyes of 8 primates, cells were delivered with a combined technique illustrated in Figure 1 . In this combined technique, the location of the saline bleb was marked externally where cells were then injected through the sclera into the preformed bleb using a 30-gauge angulated sharp tip cannula (Hurricane Medical #7509, Bradenton, FL).
Results
Approximately 20% of cells were lost from standard pipetting and redistributing the cells in a single cell suspension. A significant number of cells were also lost in the process of loading and injecting through the cannulas. Many of these cells were lost because they remain stuck to the inside of the hub of the injection cannula indicated by residual pigmentation within the needle hub. Figure 2A illustrates the percentage of cells recovered following injection through 30, 38 and 41-gauge cannulas. Figure 2B shows the percentage of the recovered cells that were viable for each size cannula. Figure 2C The serous retinal detachment produced with this surgical technique generally resolves within 24 hours to 48 hours. The histopathologic appearance of the cells in the subretinal space after 24 hours is shown in Figure 4 . Cells are present as individual cells ( Figure  4A ) and as small clumps of cells ( Figure 4B ). The retinotomy site is shown in Figure 4C .
Discussion
The findings in this study demonstrate that technical factors with the surgical delivery of cells to the subretinal space have major impacts on the number of viable cells that are successfully delivered to the subretinal space. Having a standard predictable method for delivering cells will be essential to interpret the findings from studies of cell-based therapies in animal experiments as well as in human trials.
Also of importance is minimizing the delivery of nonviable cells and cell debris into the subretinal space. Although only indirectly evaluated in this study, our results suggest that with use of smaller cannulas, a large amount of cell debris and nonviable cells are delivered into the subretinal space with smaller cannulas. It is likely this material will elicit some form of tissue reaction. Activation of microglial cells and/or greater disruption of the bloodretinal barrier are undesirable events and so the introduction of material that will need to be cleared from the subretinal space should be avoided if possible. 4 Each cell type used in cell-based therapy could have different responses to passage through a cannula. Properties of the cells, properties of the cannulas used for injection, the liquid media used with injection, and the velocity with which the cells are injected could all be variables in survival of cells.
The surgical approach to delivering cells is also an important variable affecting the number of cells successfully delivered to the subretinal space. Our experience is that there is substantial leakage of cells back into the vitreous when injecting through the retina from a vitreous approach. This leakage of cells not only reduces the number of cells in the desired subretinal location, but also increases the risk of membrane formation on the surface of the retina, and perhaps even retinal detachment. Preretinal cellular proliferations have been noted in patients undergoing trials introducing cells into the subretinal space. 1 We have found that injecting with the technique illustrated in Figure 1 is very effective in eliminating this back leakage. Although this approach is slightly more difficult technically, it relies only on skills that are very familiar to most vitreoretinal surgeons. A potential disadvantage of this approach is that there could be a greater exposure of the injected cells to uveal tissue. However, our preliminary studies with this technique have not provided any evidence of intrauveal injections.
In conclusion, the size of the cannula for injection of cells in the subretinal space needs to be optimized to allow for a standard dose of viable cells to be delivered, and to avoid delivering cell debris or nonviable cells into the subretinal space. We have found that larger cannulas are necessary for this purpose. However, use of large cannulas from a vitreous approach leads to a large amount of cell leakage into the vitreous cavity. A transscleral approach permits use of a larger cannula while still delivering the cells into the subretinal space.
Key words: cell transplantation, detachment, subretinal injection, surgical technique.
